Literature DB >> 20177787

The risk of Parkinson's disease in type 1 Gaucher disease.

Gilberto Bultron1, Katherine Kacena, Daniel Pearson, Michael Boxer, Ruhua Yang, Swati Sathe, Gregory Pastores, Pramod K Mistry.   

Abstract

In Gaucher disease, defective lysosomal glucocerebrosidase due to mutations in the GBA1 gene results in lysosomal accumulation of glucocerebroside in mononuclear phagocytes and a multisystemic phenotype. Observations of occurrence of Parkinson's disease in some patients with non-neuronopathic type 1 Gaucher disease (GD1) and their first degree relatives has led to the identification of GBA1 heterozygous mutations as a genetic risk factor for idiopathic Parkinson's disease (PD). However, the magnitude of risk of PD in patients with known GD1 has not been determined, and it is not known whether GD1/PD represents a specific sub-phenotype of GD1 with distinctive genotype/phenotype characteristics. We estimated the risk of PD in a cohort of 444 consecutively evaluated patients with GD1 compared to that in the general population. Eleven patients developed parkinsonian syndrome during a 12-year follow-up period. The adjusted life-time risk ratio of PD in GD1 compared to that in the general population was 21.4 [95% confidence interval (95% CI) 10.7-38.3], with a higher risk in men compared to women. In our cohort, GD1/Parkinson's disease phenotype (GD1/PD) was characterized by higher GD1 severity score, due to higher incidence of avascular osteonecrosis. The clinical spectrum of PD varied from mild to potentially life-threatening disease. All but one patient with GD1/PD phenotype had at least one N370S GBA1 allele. In conclusion, compared to the general population, patients with GD1 have an almost 20-fold increased life-time risk of developing PD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20177787      PMCID: PMC2887303          DOI: 10.1007/s10545-010-9055-0

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  44 in total

1.  Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features.

Authors:  R H Lachmann; D G Wight; D J Lomas; N C Fisher; J P Schofield; E Elias; T M Cox
Journal:  QJM       Date:  2000-04

2.  Parkinson's disease and the heterozygous state for glucocerebrosidase mutations among Brazilians.

Authors:  Mariana P Socal; Hugo Bock; Kristiane Michelin-Tirelli; Arlete Hilbig; Maria Luiza Saraiva-Pereira; Carlos R M Rieder; Laura B Jardim
Journal:  Parkinsonism Relat Disord       Date:  2008-03-21       Impact factor: 4.891

3.  Gaucher disease and cancer incidence: a study from the Gaucher Registry.

Authors:  Barry E Rosenbloom; Neal J Weinreb; Ari Zimran; Katherine A Kacena; Joel Charrow; Elizabeth Ward
Journal:  Blood       Date:  2005-02-17       Impact factor: 22.113

4.  Burden of parkinsonism: a population-based study.

Authors:  Mark Guttman; Pamela M Slaughter; Marc-Erick Theriault; Donald P DeBoer; C David Naylor
Journal:  Mov Disord       Date:  2003-03       Impact factor: 10.338

Review 5.  Heterozygosity for a Mendelian disorder as a risk factor for complex disease.

Authors:  E Sidransky
Journal:  Clin Genet       Date:  2006-10       Impact factor: 4.438

6.  Occurrence of Parkinson's syndrome in type I Gaucher disease.

Authors:  O Neudorfer; N Giladi; D Elstein; A Abrahamov; T Turezkite; E Aghai; A Reches; B Bembi; A Zimran
Journal:  QJM       Date:  1996-09

7.  Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson's disease in subjects of Jewish ethnicity.

Authors:  Lorraine N Clark; Angelique Nicolai; Shehla Afridi; Juliette Harris; Helen Mejia-Santana; Lisa Strug; Lucien J Cote; Elan D Louis; Howard Andrews; Cheryl Waters; Blair Ford; Steven Frucht; Stanley Fahn; Richard Mayeux; Ruth Ottman; K Marder
Journal:  Mov Disord       Date:  2005-01       Impact factor: 10.338

8.  Gaucher disease type I complicated with Parkinson's syndrome.

Authors:  Judit Várkonyi; Zsuzsa Simon; Krisztina Soós; Anna Poros
Journal:  Haematologia (Budap)       Date:  2002

9.  Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?

Authors:  N Tayebi; J Walker; B Stubblefield; E Orvisky; M E LaMarca; K Wong; H Rosenbaum; R Schiffmann; B Bembi; E Sidransky
Journal:  Mol Genet Metab       Date:  2003-06       Impact factor: 4.797

10.  Gaucher disease and the synucleinopathies.

Authors:  Kathleen S Hruska; Ozlem Goker-Alpan; Ellen Sidransky
Journal:  J Biomed Biotechnol       Date:  2006
View more
  84 in total

Review 1.  Parkinson's disease pathogenesis from the viewpoint of small fish models.

Authors:  Hideaki Matsui; Ryosuke Takahashi
Journal:  J Neural Transm (Vienna)       Date:  2017-08-02       Impact factor: 3.575

2.  Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease.

Authors:  M J Barrett; V L Shanker; W L Severt; D Raymond; S J Gross; N Schreiber-Agus; R Kornreich; L J Ozelius; S B Bressman; R Saunders-Pullman
Journal:  JIMD Rep       Date:  2014-05-22

Review 3.  Exploring the link between glucocerebrosidase mutations and parkinsonism.

Authors:  Wendy Westbroek; Ann Marie Gustafson; Ellen Sidransky
Journal:  Trends Mol Med       Date:  2011-07-01       Impact factor: 11.951

4.  A twelve-year follow-up study on a case of early-onset parkinsonism preceding clinical manifestation of Gaucher disease.

Authors:  Maciej Machaczka; Martin Paucar Arce; Malgorzata Rucinska; Takashi Yoshitake; Jan Kehr; Wojciech Jurczak; Aleksander B Skotnicki; Jan-Erik Månsson; Anna Tylki-Szymanska; Per Svenningsson
Journal:  JIMD Rep       Date:  2011-09-20

5.  Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.

Authors:  Joseph R Mazzulli; You-Hai Xu; Ying Sun; Adam L Knight; Pamela J McLean; Guy A Caldwell; Ellen Sidransky; Gregory A Grabowski; Dimitri Krainc
Journal:  Cell       Date:  2011-06-23       Impact factor: 41.582

6.  Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes.

Authors:  Roy N Alcalay; Tama Dinur; Timothy Quinn; Karina Sakanaka; Oren Levy; Cheryl Waters; Stanley Fahn; Tsvyatko Dorovski; Wendy K Chung; Michael Pauciulo; William Nichols; Huma Q Rana; Manisha Balwani; Louise Bier; Deborah Elstein; Ari Zimran
Journal:  JAMA Neurol       Date:  2014-06       Impact factor: 18.302

7.  Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease.

Authors:  Yumiko V Taguchi; Jun Liu; Jiapeng Ruan; Joshua Pacheco; Xiaokui Zhang; Justin Abbasi; Joan Keutzer; Pramod K Mistry; Sreeganga S Chandra
Journal:  J Neurosci       Date:  2017-08-28       Impact factor: 6.167

Review 8.  Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?

Authors:  Weidong Le; Jie Dong; Song Li; Amos D Korczyn
Journal:  Neurosci Bull       Date:  2017-09-02       Impact factor: 5.203

Review 9.  The link between the GBA gene and parkinsonism.

Authors:  Ellen Sidransky; Grisel Lopez
Journal:  Lancet Neurol       Date:  2012-11       Impact factor: 44.182

10.  Greater risk of parkinsonism associated with non-N370S GBA1 mutations.

Authors:  M J Barrett; P Giraldo; J L Capablo; P Alfonso; P Irun; B Garcia-Rodriguez; M Pocovi; G M Pastores
Journal:  J Inherit Metab Dis       Date:  2012-09-12       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.